Colorectal Cancer

Latest News

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.

First-Line Serplulimab Plus HLX04 Shows Manageable Safety in Advanced HCC

January 30th 2025

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.

The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.

Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC

By Roman Fabbricatore

January 27th 2025

Positive Responses Demonstrated by Adagrasib and Cetuximab in KRAS G12C-Mutant mCRC

By Ashley Chan

January 27th 2025

Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.

Fruquintinib Combo Shows Activity in Pretreated Metastatic CRC

By Jax DiEugenio

January 27th 2025

Long-term Aspirin Use Decreased PIK3CA-Mutated Colorectal Cancer Recurrence

By Kristie L. Kahl

January 26th 2025

Latest CME Events & Activities

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

...

37 38 39 40 41

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777